{"id":"NCT00423267","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)","officialTitle":"A Multicenter, Randomized, Controlled, Double-Blind, Double-Dummy, Two-Arm Study of Posaconazole vs Fluconazole in the Treatment of Coccidioidomycosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2007-01-18","resultsPosted":"2010-06-30","lastUpdate":"2017-04-11"},"enrollment":16,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Coccidioidomycosis"],"interventions":[{"type":"DRUG","name":"Posaconazole","otherNames":[]},{"type":"DRUG","name":"Fluconazole","otherNames":[]}],"arms":[{"label":"Posaconazole","type":"EXPERIMENTAL"},{"label":"Fluconazole","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the safety of posaconazole (POS) in the treatment of coccidioidomycosis. Period A consisted of 2 blinded arms, posaconazole and fluconazole. Recruitment was stopped, and participants in Period A may have been eligible to roll over to an open-label, non-comparitive Period B. During Period B, participants received posaconazole for a treatment duration not to exceed 12 months.","primaryOutcome":{"measure":"Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) or Fluconazole (FLU) in Period A","timeFrame":"12 months","effectByArm":[{"arm":"Posaconazole","deltaMin":5,"sd":null},{"arm":"Fluconazole","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["DIARRHOEA","ARTHRALGIA","ERYTHEMA","RASH","PALPITATIONS"]}}